DalsnaFinance Account

Gilead Sciences $GILD

Health Care · Biotechnology · NASDAQ

S&P 500 Nasdaq-100 Russell 1000 California

Create a scorecard

$156.51

+3.44 (+2.25%)

As of Oct 20, 2026, 9:59 PM EDT · cached

Price history

Loading chart…

Key facts

52-week range (closes): $117.85 – $155.80 Lowest close Oct 16, 2025, highest Feb 11, 2026; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
Next earnings: Oct 29, 2026, after the close · EPS forecast $2.16 Nasdaq earnings calendar, as of Oct 21, 2026
Fiscal year ends: December Fiscal 2025 ended Dec 31, 2025, from SEC filings
In the S&P 500 since: Jul 1, 2004 · All S&P 500 changes
In the Nasdaq-100 since: before 2007 · All Nasdaq-100 changes

Gilead Sciences (GILD) is trading up at $156.51 (+2.25%) on NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.

Gilead Sciences revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)

Gilead Sciences annual financial statements
	FY2016Dec 2016	FY2017Dec 2017	FY2018Dec 2018	FY2019Dec 2019	FY2020Dec 2020	FY2021Dec 2021	FY2022Dec 2022	FY2023Dec 2023	FY2024Dec 2024	FY2025Dec 2025
Income statement
Revenue	$30.4B	$26.1B	$22.1B	$22.4B	$24.7B	$27.3B	$27.3B	$27.1B	$28.8B	$29.4B
Growth (year over year)	−6.9%	−14.1%	−15.2%	+1.5%	+10.0%	+10.6%	−0.1%	−0.6%	+6.0%	+2.4%
Gross profit	$26.1B	$21.7B	$17.3B	$17.8B	$20.1B	$20.7B	$21.6B	$20.6B	$22.5B	$23.2B
Gross margin	86.0%	83.3%	78.1%	79.2%	81.5%	75.8%	79.3%	76.0%	78.3%	78.8%
Operating income	$17.6B	$14.1B	$8.20B	$4.29B	$4.07B	$9.92B	$7.33B	$7.61B	$1.66B	$10.0B
Operating margin	58.0%	54.1%	37.1%	19.1%	16.5%	36.3%	26.9%	28.0%	5.8%	34.0%
Net income	$13.5B	$4.63B	$5.46B	$5.39B	$123.0M	$6.22B	$4.59B	$5.67B	$480.0M	$8.51B
Net margin	44.4%	17.7%	24.7%	24.0%	0.5%	22.8%	16.8%	20.9%	1.7%	28.9%
EPS (diluted)	$9.94	$3.51	$4.17	$4.22	$0.10	$4.93	$3.64	$4.50	$0.38	$6.78
Balance sheet
Cash and equivalents	$8.23B	$7.59B	$17.9B	$11.6B	$6.00B	$5.34B	$5.41B	$6.08B	$9.99B	$7.56B
Total assets	$57.0B	$70.3B	$63.7B	$61.6B	$68.4B	$68.0B	$63.2B	$62.1B	$59.0B	$59.0B
Total liabilities	$37.6B	$49.8B	$42.1B	$39.0B	$50.2B	$46.9B	$42.0B	$39.4B	$39.7B	$36.4B
Long-term debt	$26.3B	$30.8B	$24.6B	$22.1B	$28.6B	$25.2B	$23.0B	$23.2B	$24.9B	$22.1B
Shareholders' equity	$18.9B	$20.4B	$21.4B	$22.5B	$18.2B	$21.1B	$21.2B	$22.8B	$19.3B	$22.7B
Cash flow
Operating cash flow	$17.0B	$11.9B	$8.40B	$9.14B	$8.17B	$11.4B	$9.07B	$8.01B	$10.8B	$10.0B
Capital expenditure	$748.0M	$590.0M	$924.0M	$825.0M	$650.0M	$579.0M	$728.0M	$585.0M	$523.0M	$563.0M
Free cash flow	$16.3B	$11.3B	$7.48B	$8.32B	$7.52B	$10.8B	$8.34B	$7.42B	$10.3B	$9.46B
Dividends paid	$2.46B	$2.73B	$2.97B	$3.22B	$3.45B	$3.60B	$3.71B	$3.81B	$3.92B	$4.00B
Share buybacks	$11.0B	$954.0M	$2.90B	$1.75B	$1.58B	$546.0M	$1.40B	$1.00B	$1.15B	$1.92B

RevenueNet incomeNet margin (right axis, %)

Gilead Sciences quarterly financial statements
	Q3 FY24Sep 2024	Q4 FY24^†Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25^†Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Income statement
Revenue	$7.54B	$7.57B	$6.67B	$7.08B	$7.77B	$7.92B	$6.96B	$7.80B
Growth (year over year)	+7.0%	+6.4%	−0.3%	+1.8%	+3.0%	+4.7%	+4.4%	+10.2%
Gross profit	$5.97B	$5.99B	$5.13B	$5.58B	$6.20B	$6.30B	$5.51B	$6.22B
Gross margin	79.1%	79.1%	76.9%	78.8%	79.8%	79.5%	79.2%	79.8%
Operating income	$888.0M	$2.45B	$2.24B	$2.47B	$3.33B	$1.98B	$2.59B	−$10.4B
Operating margin	11.8%	32.4%	33.6%	34.9%	42.8%	25.0%	37.2%	−133.2%
Net income	$1.25B	$1.78B	$1.31B	$1.96B	$3.05B	$2.18B	$2.02B	−$10.5B
Net margin	16.6%	23.6%	19.7%	27.7%	39.3%	27.5%	29.0%	−134.5%
EPS (diluted)	$1.00	$1.43	$1.04	$1.56	$2.43	$1.75	$1.61	−$8.45
Balance sheet
Cash and equivalents	$5.04B	$9.99B	$7.93B	$5.14B	$7.33B	$7.56B	$7.63B	$3.18B
Total assets	$54.5B	$59.0B	$56.4B	$55.7B	$58.5B	$59.0B	$56.3B	$49.4B
Total liabilities	$36.1B	$39.7B	$37.4B	$36.1B	$37.1B	$36.4B	$32.8B	$37.6B
Long-term debt	$21.4B	$24.9B	$22.1B	$22.1B	$22.1B	$22.1B	$20.9B	$23.8B
Shareholders' equity	$18.5B	$19.3B	$19.2B	$19.7B	$21.5B	$22.7B	$23.5B	$11.8B
Cash flow
Operating cash flow	$4.31B	$2.98B	$1.76B	$827.0M	$4.11B	$3.33B	$2.54B	$3.57B
Capital expenditure	$141.0M	$147.0M	$104.0M	$107.0M	$147.0M	$205.0M	$117.0M	$140.0M
Free cash flow	$4.17B	$2.83B	$1.65B	$720.0M	$3.96B	$3.12B	$2.43B	$3.43B
Dividends paid	$983.0M	$973.0M	$1.01B	$994.0M	$1.00B	$994.0M	$1.04B	$1.03B
Share buybacks	$300.0M	$350.0M	$730.0M	$527.0M	$435.0M	$230.0M	$419.0M	$355.0M

From Gilead Sciences's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Gilead Sciences vs the Health Care sector and the S&P 500

Gilead Sciences's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.

Gilead Sciences compared with the median Health Care company and the median S&P 500 company
Measure	Gilead Sciences	Health Care (59 other S&P 500 companies)	S&P 500 (502 other companies)
Revenue growth, latest fiscal year	+2.4%	+7.2%	+7.0%
Net margin, latest fiscal year	28.9%	12.9%	12.9%
Dividend per share, latest fiscal year	$3.16	$2.43	$2.40
Share price change, 1 year	+27.1%	+22.0%	+7.5%

Gilead Sciences: fiscal year ended December 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Gilead Sciences included, are the last regular-session prices of October 20, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, dividend per share 32/349, 1-year price change 59/488; the reasons below can overlap. 14 are left out of the price figure because our archive holds no comparable close for them; dividend medians are among the 32 sector and 349 S&P 500 companies reporting a per-share dividend. The S&P 500 price figure is the middle company's change, not the index's return.

About Gilead Sciences

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.

Source: Wikipedia — Gilead Sciences